Alfuzosin
- Generic Name
- Alfuzosin
- Brand Names
- Uroxatral, Xatral
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N5O4
- CAS Number
- 81403-80-7
- Unique Ingredient Identifier
- 90347YTW5F
- Background
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
- Indication
Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions
- Conditions
- Healthy Vollunteer
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Pharma Nueva
- Target Recruit Count
- 44
- Registration Number
- NCT06316336
The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- International Bio service
- Target Recruit Count
- 44
- Registration Number
- NCT06228339
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil
- Conditions
- Choroid DiseaseBenign Prostatic HyperplasiaPupil Anomaly
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Kocatepe University
- Target Recruit Count
- 63
- Registration Number
- NCT03144596
Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hypertrophy With Outflow ObstructionBenign Prostatic Hyperplasia
- Interventions
- Dietary Supplement: Odyliresin
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 30
- Registration Number
- NCT02977832
- Locations
- 🇮🇹
Urology Department Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02266537
Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 74
- Registration Number
- NCT01834729
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Benign Prostatic Hyperplasia in Taiwan
- Conditions
- Prostatic Diseases
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 362
- Registration Number
- NCT00941343
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Taipei, Taiwan
An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
- Conditions
- Lower Urinary Tract SymptomsErectile Dysfunction
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Chesapeake Urology Research Associates
- Target Recruit Count
- 74
- Registration Number
- NCT00893113
- Locations
- 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
Evaluation of Symptom-specific Goal Achievement
- Conditions
- Benign Prostatic HyperplasiaLower Urinary Tract Symptoms
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 130
- Registration Number
- NCT00836823
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of
Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
- Conditions
- Kidney Stones
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- United States Naval Medical Center, San Diego
- Target Recruit Count
- 240
- Registration Number
- NCT00713739
- Locations
- 🇺🇸
Naval Medical Center San Diego, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.